CCatalent provides end-to-end contract development and manufacturing services for pharmaceutical, biotechnology, and consumer health products. Its offerings cover drug formulation, large-scale manufacturing, clinical supply, and packaging under long-term partnerships, coordinating through a connected supply chain to move products from development to market. It differentiates itself with a broad, integrated service platform and long-standing customer relationships that help clients accelerate development and ensure reliable supply. The company aims to help clients bring products to market efficiently while balancing quality, cost, and sustainability across the product lifecycle.
Work here?Claim your company
Industries
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Franklin Township, NJ
Founded
1996
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$5.3B
Above
Industry Average
Funded Over
4 Rounds
Catalent has appointed Wetteny Joseph as group president of its Pharma and Consumer Health (PCH) segment, effective November 2, 2026. The contract development and manufacturing organisation (CDMO) is based in Tampa, Florida. Joseph will lead the segment, which focuses on oral delivery technologies and manufacturing for small and macro molecules, as well as self-care solutions. He joins the group executive committee and reports to chief executive officer Alessandro Maselli. Joseph joins from Zoetis, where he was chief financial officer. He previously served Catalent as chief financial officer and as president of Clinical Supply Services. He succeeds Aris Gennadios, who is leaving after a career at Catalent that began in 2002. "Wetteny is an accomplished leader with a deep understanding of our industry, our customers and Catalent," said Maselli.
Catalent appoints Wetteny Joseph Group President, Pharma and Consumer Health. Tampa, Fla. - Nov. 2, 2026 - Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, has appointed Wetteny Joseph as Group President, Pharma and Consumer Health (PCH), effective today. Joseph will lead Catalent's PCH segment focusing on oral delivery technologies and manufacturing for small and macro molecules, and advanced delivery of self-care solutions, joining Catalent's Group Executive Committee and reporting directly to Alessandro Maselli, President and Chief Executive Officer. Joseph succeeds Aris Gennadios, Ph.D., who is leaving to pursue outside opportunities after a long-tenured career at Catalent that began in 2002. "Wetteny is an accomplished leader with a deep understanding of our industry, our customers and Catalent," said Maselli. "His commitment to operational excellence, customer partnership and value creation makes him exceptionally well positioned to lead the next chapter of growth for our PCH business." Joseph brings extensive global leadership experience and a strong track record of driving business growth and transformation. He joins Catalent from Zoetis, where he served as Executive Vice President and Chief Financial Officer, overseeing financial management, planning, operations, indirect procurement and the company's Human Health Diagnostics business. He previously held senior leadership roles at Catalent, including Senior Vice President and Chief Financial Officer and President of Clinical Supply Services, where he oversaw accelerated financial growth and value creation through transformational acquisitions and strategic investments. "I look forward to partnering with the talented PCH team to build on its strong foundation and deliver for our customers and the patients they serve," said Joseph. "I share Catalent's commitment to putting patients first and delivering unparalleled service, and I'm excited about the opportunity to champion our customers' missions while driving sustainable growth." About Catalent. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers' needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
Catalent appoints Wetteny Joseph as Pharma and Consumer Health President. Former Catalent executive and current Zoetis CFO Wetteny Joseph returns to lead the CDMO's Pharma and Consumer Health segment. November 2, 2026 Associate Editor, Contract Pharma Catalent has appointed Wetteny Joseph as Group President, Pharma and Consumer Health (PCH), effective immediately, placing a former company executive and current Zoetis CFO in charge of one of its key operating segments. In the role, Joseph will lead Catalent's Pharma and Consumer Health business, which includes oral delivery technologies, manufacturing for small- and large-molecule products, and self-care solutions. He will join the company's Group Executive Committee and report directly to President and CEO Alessandro Maselli. Joseph succeeds Aris Gennadios, Ph.D., who is leaving the CDMO after a tenure that began in 2002. The appointment marks a return to Catalent for Joseph, who previously served as the company's Senior Vice President and CFO, as well as President of Clinical Supply Services. Most recently, he was Executive Vice President and CFO at Zoetis, where he oversaw finance, planning, operations, indirect procurement, and the company's Human Health Diagnostics business. "Wetteny is an accomplished leader with a deep understanding of our industry, our customers and Catalent," Alessandro Maselli said in a statement. "His commitment to operational excellence, customer partnership and value creation makes him exceptionally well positioned to lead the next chapter of growth for our PCH business." Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Esteve earmarks $80M to revamp CDMO operations in China. Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling its China operations in the service of its global ambitions. The CDMO just announced an $80 million investment to relocate, modernize and expand its Chinese manufacturing footprint. The new site in Shaoxing will include three new workshops and reserve 150 m^3 of reactor volume for future development, allowing potential total volume to reach more than 400 m^3. Esteve said the new facilities will significantly increase the company's capabilities in Asia. "This investment is an important step in the sustained growth of Esteve CDMO and our global manufacturing platform," Joan Petit, president of Esteve CDMO, said in an Oct. 21 statement. "Strengthening our presence in China allows us to bring our capabilities closer to customers in Asia while leveraging the expertise of our global network." The China expansion is part of Esteve's pivot toward a global development and manufacturing presence. In 2025, the CDMO established an American flagship location at its Morton Grove, Illinois, facility, gleaned from its acquisition of Regis Technology. Esteve didn't disclose the initial deal price, but it has since publicly invested an additional $33 million to upgrade the facility, which offers services ranging from early-stage R&D to active pharmaceutical ingredient (API) manufacturing. Esteve's recent expansion spree reflects a larger transformation underway in the CDMO sector. As cell therapies, precision medicines and other advanced treatments demand more specialized manufacturing expertise, contract manufacturers are racing to become full-service development partners. CDMOs are rapidly adding locations, expanding technical capabilities and pursuing new technologies. Catalent just signed on as a partner to Ori Biotech, giving it access to the next-gen automated cell-therapy platform tech, Iro. This summer, Swiss-based Lonza announced plans to increase its capacity to produce components of antibody drug conjugates (ADC) and ultimately offer a start-to-finish ADC service. And Belgium's Ardena has positioned itself as a one-stop-shop CDMO for biotechs developing precision medicines. For its part, Esteve said in a statement that building an integrated global network of manufacturing sites has allowed the company to support "the increasingly complex requirements of small-molecule API development and manufacturing for customers across China, Asia and international markets."
Alessandro Maselli joins industry leaders to celebrate biotech innovation and the future of healthcare at Endpoints 11. Catalent President & CEO, Alessandro Maselli, recently joined biotechnology leaders to recognize eleven of the sector's most promising startups and founders at the 2026 Endpoints 11 Awards. Hosted by Endpoints News, the Endpoints 11 Awards recognize emerging biotechnology companies whose scientific innovation and bold vision are advancing the next generation of medicines and therapies. This annual event brings together industry leaders, investors and scientists to celebrate excellence and recognize the companies helping drive the future of healthcare. In his welcome remarks, Alessandro addressed the forces reshaping the environment for biotech, including emerging science, changing investment conditions, evolving global development pathways and the impact of AI. He highlighted the importance of moving with speed, engaging the right partners early and keeping patients at the center of decision-making. His remarks reinforced Catalent's longstanding commitment to partnering with innovators as they advance promising therapies to patients. View the 2026 Endpoints 11 Awards ceremony on the Endpoints News website: https://events.endpoints.news/eleven26
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Franklin Township, NJ
Founded
1996
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs